title: Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
abstract: BACKGROUND
  Ethnic differences in drug susceptibility and toxicity are a major concern, not only in drug development but also in the clinical setting. We review the toxicity profiles of docetaxel according to dose and ethnicity.
  
  
  METHODS
  We analyzed phase II and III clinical trials that included a once-every-3-weeks single-agent docetaxel arm. Logistic regression analysis was applied to identify the significant variables affecting the reported incidence of docetaxel-induced severe neutropenia.
  
  
  RESULTS
  Multivariate logistic regression analysis identified studies conducted in Asia [odds ratio (OR) 19.0; 95% confidence interval (95% CI) 3.64-99.0] and docetaxel dose (OR 1.08; 95% CI 1.03-1.13) as independent variables for the incidence of grade 3/4 neutropenia.
  
  
  CONCLUSIONS
  There is a significant difference in the incidence of docetaxel-induced severe neutropenia between Asian and non-Asian clinical studies. Physicians and pharmacists should consider ethnic diversity in docetaxel toxicity when interpreting the results of clinical trials.
authors.affiliation: Department of Pharmacy, University of Fukui Hospital, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan. yanor@u-fukui.ac.jp
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Yano
authors.forename: Aya
authors.initials: A
authors.lastname: Konno
authors.forename: Kyohei
authors.initials: K
authors.lastname: Watanabe
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tsukamoto
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Kayano
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ohnaka
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Goto
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Nakamura
authors.forename: Mikio
authors.initials: M
authors.lastname: Masada
mesh_terms: D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005006:Ethnicity / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology*; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology / Q000473:pathology*; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
chemical_list: D043823:Taxoids; D000077143:Docetaxel
references.citation: Br J Cancer. 2002 Nov 18;87(11):1210-5
references.pmid: 12439707
references.citation: J Clin Oncol. 1997 May;15(5):1853-7
references.pmid: 9164195
references.citation: Anticancer Res. 2003 Sep-Oct;23(5b):4219-22
references.pmid: 14666628
references.citation: Br J Cancer. 2008 May 20;98(10):1608-13
references.pmid: 18475293
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4963-70
references.pmid: 17033039
references.citation: Ann Oncol. 1994 May;5(5):468-70
references.pmid: 7915537
references.citation: Br J Cancer. 2005 Jan 17;92(1):15-20
references.pmid: 15597104
references.citation: Cancer. 1995 Feb 15;75(4):968-72
references.pmid: 7842417
references.citation: Cancer Chemother Pharmacol. 2008 Apr;61(4):631-7
references.pmid: 17520252
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3540-6
references.pmid: 19470925
references.citation: J Clin Oncol. 1999 May;17(5):1413-24
references.pmid: 10334526
references.citation: Cancer Chemother Pharmacol. 2004 Sep;54(3):230-6
references.pmid: 15127232
references.citation: Gan To Kagaku Ryoho. 1994 Nov;21(15):2625-32
references.pmid: 7979423
references.citation: Br J Cancer. 2005 Oct 31;93(9):999-1004
references.pmid: 16234823
references.citation: Eur J Cancer. 1994;30A(8):1061-4
references.pmid: 7654429
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4522-9
references.pmid: 19687336
references.citation: Breast Cancer. 2004;11(4):374-9
references.pmid: 15604993
references.citation: J Clin Oncol. 1995 Mar;13(3):645-51
references.pmid: 7884425
references.citation: Ann Oncol. 2009 Jul;20(7):1210-5
references.pmid: 19254942
references.citation: Med Oncol. 2007;24(1):71-5
references.pmid: 17673814
references.citation: Br J Cancer. 1999 May;80(3-4):438-43
references.pmid: 10408850
references.citation: Lung Cancer. 2000 Sep;29(3):205-16
references.pmid: 10996423
references.citation: Cancer Chemother Pharmacol. 1999;44(3):253-8
references.pmid: 10453728
references.citation: J Cancer Res Clin Oncol. 2008 Feb;134(2):125-35
references.pmid: 17636328
references.citation: J Clin Oncol. 2000 Jan;18(1):131-5
references.pmid: 10623703
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5542-51
references.pmid: 16110015
references.citation: Gan To Kagaku Ryoho. 1998 Oct;25(12):1915-24
references.pmid: 9797814
references.citation: J Clin Oncol. 2009 May 20;27(15):2530-5
references.pmid: 19349543
references.citation: Jpn J Clin Oncol. 2005 Dec;35(12):700-6
references.pmid: 16303792
references.citation: Invest New Drugs. 1998-1999;16(3):265-70
references.pmid: 10360607
references.citation: Gynecol Oncol. 2003 Feb;88(2):130-5
references.pmid: 12586591
references.citation: Eur J Cancer. 2000 May;36(8):1016-25
references.pmid: 10885606
references.citation: Clin Pharmacol Ther. 2008 Sep;84(3):287-94
references.pmid: 18714314
references.citation: Jpn J Clin Oncol. 2000 Oct;30(10):429-34
references.pmid: 11185888
references.citation: Ann Oncol. 1994 Jul;5(6):533-7
references.pmid: 7918125
references.citation: Lung Cancer. 2008 Jan;59(1):57-63
references.pmid: 17765354
references.citation: Br J Cancer. 1994 Aug;70(2):380-3
references.pmid: 7914428
references.citation: Anticancer Drugs. 2006 Apr;17(4):401-9
references.pmid: 16549997
references.citation: Clin Cancer Res. 1996 May;2(5):837-42
references.pmid: 9816238
references.citation: Med Oncol. 1996 Jun;13(2):87-93
references.pmid: 9013471
references.citation: Gan To Kagaku Ryoho. 1999 Mar;26(4):487-96
references.pmid: 10097745
references.citation: Clin Cancer Res. 2009 Aug 1;15(15):4806-14
references.pmid: 19622575
references.citation: J Thorac Oncol. 2007 Apr;2(4):306-11
references.pmid: 17409802
references.citation: Ann Oncol. 2004 Sep;15(9):1358-65
references.pmid: 15319242
references.citation: Ann Oncol. 2007 Jun;18(6):1064-70
references.pmid: 17434899
references.citation: Br J Cancer. 1998 Nov;78(10):1342-5
references.pmid: 9823976
references.citation: Am J Clin Oncol. 2003 Oct;26(5):477-82
references.pmid: 14528074
references.citation: Oncology. 2001;60(1):60-5
references.pmid: 11150910
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4270-7
references.pmid: 17878479
references.citation: Am J Clin Oncol. 1999 Feb;22(1):78-81
references.pmid: 10025387
references.citation: Cell. 1991 Jul 12;66(1):85-94
references.pmid: 1712673
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1061-9
references.pmid: 15657405
references.citation: Jpn J Clin Oncol. 2002 Jul;32(7):248-54
references.pmid: 12324575
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5034-42
references.pmid: 17075123
references.citation: Cancer Chemother Pharmacol. 2009 Sep;64(4):763-8
references.pmid: 19241078
references.citation: Ann Oncol. 1994 Jul;5(6):527-32
references.pmid: 7918124
references.citation: J Clin Oncol. 2000 May;18(10):2081-6
references.pmid: 10811673
references.citation: J Clin Oncol. 1996 Jan;14(1):58-65
references.pmid: 8558221
references.citation: J Clin Oncol. 2004 Jul 1;22(13):2602-9
references.pmid: 15226327
references.citation: Ann Oncol. 1994 Jul;5(6):539-42
references.pmid: 7918126
references.citation: J Clin Oncol. 1994 Nov;12(11):2301-8
references.pmid: 7964944
references.citation: Ann Oncol. 2005 Feb;16(2):294-9
references.pmid: 15668287
references.citation: Semin Oncol. 1999 Oct;26(5 Suppl 17):19-23
references.pmid: 10604264
references.citation: Cancer J Sci Am. 1999 Jul-Aug;5(4):237-41
references.pmid: 10439170
references.citation: Am J Clin Oncol. 2006 Aug;29(4):389-94
references.pmid: 16891868
references.citation: Cancer Chemother Pharmacol. 2006 Jul;58(1):40-9
references.pmid: 16284790
references.citation: Ann Oncol. 2001 Sep;12(9):1281-8
references.pmid: 11697841
references.citation: J Clin Oncol. 1995 Dec;13(12):2895-9
references.pmid: 8523052
references.citation: Br J Cancer. 1994 Aug;70(2):376-9
references.pmid: 7914427
references.citation: J Clin Oncol. 2008 Sep 10;26(26):4244-52
references.pmid: 18779611
references.citation: J Clin Oncol. 2006 May 1;24(13):2038-43
references.pmid: 16648503
references.citation: Br J Cancer. 2006 May 8;94(9):1233-6
references.pmid: 16622454
references.citation: Lung Cancer. 2000 Mar;27(3):145-57
references.pmid: 10699688
references.citation: J Clin Oncol. 1998 Oct;16(10):3362-8
references.pmid: 9779713
references.citation: Gan To Kagaku Ryoho. 1994 Oct;21(14):2431-7
references.pmid: 7944488
references.citation: Chest. 2006 Apr;129(4):1031-8
references.pmid: 16608954
references.citation: Ann Oncol. 2004 Jan;15(1):38-44
references.pmid: 14679117
references.citation: Br J Cancer. 2004 Dec 13;91(12):1996-2004
references.pmid: 15558071
references.citation: BJU Int. 2008 Nov;102(9):1080-5
references.pmid: 18485028
references.citation: J Clin Oncol. 2000 May;18(10):2095-103
references.pmid: 10811675
references.citation: Cancer Invest. 2002;20(4):464-72
references.pmid: 12094541
references.citation: Cancer. 2008 Apr 1;112(7):1455-61
references.pmid: 18300256
references.citation: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references.pmid: 16257339
references.citation: Ann Oncol. 2000 May;11(5):541-6
references.pmid: 10907946
references.citation: J Clin Oncol. 1994 Jun;12(6):1232-7
references.pmid: 7911159
references.citation: Ann Oncol. 2002 Mar;13(3):412-5
references.pmid: 11996472
references.citation: Gan To Kagaku Ryoho. 1994 Oct;21(14):2471-7
references.pmid: 7944493
references.citation: Cancer Res. 1996 Mar 15;56(6):1296-302
references.pmid: 8640817
references.citation: Gan To Kagaku Ryoho. 1994 Nov;21(15):2609-16
references.pmid: 7979421
references.citation: Invest New Drugs. 2002 Feb;20(1):95-9
references.pmid: 12003198
references.citation: J Clin Oncol. 1995 Dec;13(12):2886-94
references.pmid: 8523051
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Ann Oncol. 2004 Jun;15(6):955-9
references.pmid: 15151954
references.citation: J Clin Oncol. 2005 Nov 20;23(33):8389-95
references.pmid: 16293869
references.citation: Jpn J Clin Oncol. 2008 May;38(5):365-72
references.pmid: 18417502
references.citation: Anticancer Drugs. 1996 Jun;7(4):398-401
references.pmid: 8826607
references.citation: Ann Oncol. 2005 Jan;16(1):90-6
references.pmid: 15598944
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3611-9
references.pmid: 19470941
references.citation: J Clin Oncol. 1998 Jan;16(1):187-96
references.pmid: 9440742
references.citation: J Clin Oncol. 1994 Jun;12(6):1238-44
references.pmid: 7911160
references.citation: Ann Oncol. 1996 Feb;7(2):165-71
references.pmid: 8777173
references.citation: Eur J Cancer. 1994;30A(8):1058-60
references.pmid: 7654428
references.citation: Am J Clin Oncol. 2007 Aug;30(4):428-31
references.pmid: 17762444
references.citation: Ann Oncol. 2000 Dec;11(12):1531-6
references.pmid: 11205459
references.citation: J Clin Oncol. 1999 Aug;17(8):2341-54
references.pmid: 10561296
references.citation: J Clin Oncol. 1995 Dec;13(12):2879-85
references.pmid: 8523050
references.citation: Oncology. 2006;70(2):154-8
references.pmid: 16645329
references.citation: Gan To Kagaku Ryoho. 1995 Jan;22(1):59-65
references.pmid: 7826079
references.citation: Med Oncol. 2007;24(4):407-12
references.pmid: 17917090
references.citation: J Clin Oncol. 1997 Oct;15(10):3275-9
references.pmid: 9336365
references.citation: Cancer Invest. 2004;22(3):353-9
references.pmid: 15493355
references.citation: N Engl J Med. 2002 Jan 10;346(2):85-91
references.pmid: 11784874
references.citation: Ann Oncol. 2006 Mar;17(3):467-72
references.pmid: 16371411
references.citation: Br J Cancer. 1996 Aug;74(4):650-6
references.pmid: 8761385
references.citation: Ann Oncol. 2003 Jan;14(1):116-22
references.pmid: 12488303
references.citation: Gan To Kagaku Ryoho. 1994 Oct;21(14):2453-60
references.pmid: 7944491
references.citation: Clin Lung Cancer. 2008 May;9(3):154-9
references.pmid: 18621625
references.citation: Eur J Cancer. 2001 Oct;37(15):1833-8
references.pmid: 11576836
references.citation: Acta Oncol. 2000;39(2):225-9
references.pmid: 10859016
references.citation: Anticancer Res. 2008 Nov-Dec;28(6B):3993-5
references.pmid: 19192662
references.citation: Br J Cancer. 2008 Sep 16;99(6):852-7
references.pmid: 18728643
references.citation: Ann Oncol. 2009 May;20(5):835-41
references.pmid: 19164456
references.citation: Lancet. 2008 Nov 22;372(9652):1809-18
references.pmid: 19027483
references.citation: J Clin Oncol. 1996 May;14(5):1649-55
references.pmid: 8622084
references.citation: J Clin Oncol. 1995 Feb;13(2):314-22
references.pmid: 7844592
references.citation: Gan To Kagaku Ryoho. 1994 Nov;21(15):2617-23
references.pmid: 7979422
references.citation: Br J Cancer. 1996 Jan;73(2):210-6
references.pmid: 8546908
references.citation: Gan To Kagaku Ryoho. 1999 Jan;26(1):107-16
references.pmid: 9987506
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3657-63
references.pmid: 16877734
references.citation: J Clin Oncol. 2004 May 1;22(9):1589-97
references.pmid: 15117980
references.citation: Cancer Invest. 1998;16(5):314-8
references.pmid: 9627678
references.citation: Med Oncol. 1996 Jun;13(2):111-7
references.pmid: 9013474
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2800-7
references.pmid: 16682727